Advertisement
Advertisement
CNTB
Connect Biopharma Holdings Limited Ordinary Shares
0.68
USDSponsored
-0.07
-9.08%
Nov 10, 15:59 UTC -5
Closed
After-Market
0.70
+0.02
+2.61%
Connect Biopharma Holdings Limited Ordinary Shares (CNTB) Earnings
CNTB Earnings Reports
Positive Surprise Ratio
CNTB beat 5 of 7 last estimates.
71%
Next Report
Today
Date of Next Report
Nov 10, 2026
Estimate for Q3 26 (Revenue/ EPS)
$786.86K
/-$0.27
Implied change from Q2 26 (Revenue/ EPS)
-71.57%
/--
Implied change from Q3 25 (Revenue/ EPS)
+4817.86%
/+575.00%
Connect Biopharma Holdings Limited Ordinary Shares earnings per share and revenue
On Aug 12, 2026, CNTB reported earnings of -0.27 USD per share (EPS) for Q2 26, beating the estimate of -0.32 USD, resulting in a 15.97% surprise. Revenue reached 2.77 million, compared to an expected 663.00 thousand, with a 317.50% difference. The market reacted with a +9.01% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 3 analysts forecast an EPS of -0.27 USD, with revenue projected to reach 786.86 thousand USD, implying an increase of 0.00% EPS, and decrease of -71.57% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
TELA Bio, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.16
Actual
-$0.13
Surprise
+20.54%
Atossa Therapeutics, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.90
Actual
-$0.56
Surprise
+38.31%
CalciMedica, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$1.30
Actual
-$0.72
Surprise
+44.64%
Scholar Rock Holding Corporation Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.86
Actual
-$0.81
Surprise
+6.18%
Kura Oncology, Inc.
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.83
Actual
-$0.78
Surprise
+7.00%
Olema Pharmaceuticals, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.63
Actual
-$0.73
Surprise
-14.53%
Autolus Therapeutics plc - ADR
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.16
Actual
-$0.21
Surprise
-27.20%
Protalix BioTherapeutics, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.03
Actual
$0.05
Surprise
+265.02%
PepGen Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.27
Actual
-$0.28
Surprise
-1.19%
Humacyte, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.09
Actual
-$0.07
Surprise
+22.91%
FAQ
What were Connect Biopharma Holdings Limited Ordinary Shares's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Connect Biopharma Holdings Limited Ordinary Shares reported EPS of -$0.27, beating estimates by 15.97%, and revenue of $2.77M, 317.5% above expectations.
How did the market react to Connect Biopharma Holdings Limited Ordinary Shares's Q2 2026 earnings?
The stock price moved up 9.01%, changed from $2.33 before the earnings release to $2.54 the day after.
When is Connect Biopharma Holdings Limited Ordinary Shares expected to report next?
The next earning report is scheduled for Nov 10, 2026.
What are the forecasts for Connect Biopharma Holdings Limited Ordinary Shares's next earnings report?
Based on 3
analysts, Connect Biopharma Holdings Limited Ordinary Shares is expected to report EPS of -$0.27 and revenue of $786.86K for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.